Australian & New Zealand Psychedelic Medicine Clinical Trials
A comprehensive guide about the characteristics and distinctons between various psychedelic substances.
NEO Exchange – February 2021
Psych Scene Hub – 31/10/2020
Psychedelics are any of the so-caled mind-exanding drugs that are able to induce states of altered perception and thoughts, frenquently with a heightened awareness of sensory input but with diminised control over what’s being experienced.
|Psychedelic medicine||Outcome||Status||Study details||Location||Contact details|
|Psilocybin||Methamphetamine addiction||Not yet recruiting||See study details||Australia||Dr Jonathan Brett
Dr Elizabeth Knock
St. Vincent’s Hospital Darlinghurst
To be announced
|End-of-life psychological distress||Recruiting||See study details||Australia||Ms Virginia Francis
St. Vincent’s Hospital Melbourne
+61 3 9231 2211
|MDMA||Advanced-stage cancer mood and anxiety||Not yet recruiting||See study details||New Zealand||Prof Paul Glue
University of Otago
+64 3 474 0999
|Attitudes towards treating Post-Traumatic Stress Disorder||Recruiting||See study details||Australia||Dr Dean Wright
University of Technology Sydney
+61 2 9114 4343
|LSD||Microdosing||Not yet recruiting||See study details||New Zealand||A/Prof Suresh Muthukumaraswamy
The University of Auckland
+64 9 373 7599
|Psychedelic medicine||Outcome||Level of evidence||Magnitude of effect||Consistency of research results||Notes|
|Ibogaine||Addiction||Significant||High||A single ibogaine dose may lead to opioid dependence cessation with long-term reduction in dependence sustained. Ibogaine’s main metabolite leading to therapeutic outcomes is noribogaine. Results must be replicated in high-quality studies to support these observational results.|
|MDMA||Tinnitus||Significant||High||Following MDMA administration, tinnitus rating significantly improved. There is, however, a placebo effect. There is sufficient proof-of-concept to support future investigation of MDMA as a treatment for tinnitus.|
|Level of evidence||Robust research conducted with repeated double-blind clinical trials||Multiple studies where at least two are double-blind and placebo controlled||Single double-blind study or multiple cohort studies||Uncontrolled or observational studies only|
Research analysis led by: Victor Chiruta
Reviewed by: Mind Medicine Australia Team
Last updated: 22 April, 2021
UHSc, MCMA, MPS
Victor Chiruta has over ten years experience working in the health industry. He is in his final year of a Bachelor of Health Science and organising a proposal for an Honours in Biomedical Research at the University of South Australia. He has further completed study and certification in youth work, biochemistry, naturopathy, homeopathy, medicinal chemistry, pharmacology, biology, and medicinal cannabis consulting. Victor is a Certified SMART Recovery Australian Facilitator, a Professional Interpener (cannabis sommelier), registered internationally as a naturopath and homeopath, a TGA sponsor administrator and a member of several professional bodies.
He is one of Mind Medicine Australia’s key researchers, scientific writers, and a board member of the Brisbane chapter. Outside of Mind Medicine Australia, Victor provides hospital equipment to public hospitals, is involved with the National Disability Insurance Scheme, and develops health and medical foods utilising his rich passion for pharmacology, medicinal and biochemistry. His particular interests lie in psychedelic medicines, phytocannabinoids, disability rehabilitation, and anabolic phytosteroids.